Alto Neuroscience, Inc. (ANRO): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$51.77M

Year ended 2025-12-31

-$68.28M

Trailing 12 months to 2026-06-30

2023-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$51.77M	n/m	2026-03-16, From 2025-01-01
2024-12-31	-$47.42M	n/m	2026-03-16, From 2024-01-01
2023-12-31	-$33.45M	n/a	2025-03-20, From 2023-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Alto Neuroscience, Inc. (ANRO)	2025-12-31	-$51.77M	n/m
Lexicon Pharmaceuticals, Inc. (LXRX)	2025-12-31	-$67.85M	n/m
Fortress Biotech, Inc. (FBIO)	2025-12-31	-$65.78M	n/m
Benitec Biopharma Inc. (BNTC)	2026-06-30	-$16.52M	n/m
Adicet Bio, Inc. (ACET)	2025-12-31	-$95.25M	n/m
Trevi Therapeutics, Inc. (TRVI)	2025-12-31	-$42.09M	n/m
PepGen Inc. (PEPG)	2025-12-31	-$81.64M	n/m
Gossamer Bio, Inc. (GOSS)	2025-12-31	-$171.27M	n/m
Foghorn Therapeutics Inc. (FHTX)	2025-12-31	-$86.10M	n/m

Compare ANRO, LXRX, FBIO, BNTC side by side · Screen every company in Pharmaceutical Preparations ↗